> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Cobenfy Effective as Schizophrenia Adjunct: Trial
- URL: https://www.fdaweb.com/cobenfy-effective-as-schizophrenia-adjunct-trial/
- Published: 2025-04-23T12:00:00.000Z
- Updated: 2026-09-14T15:10:08.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5159049

Bristol Myers Squibb says its Cobenfy (xanomeline and trospium chloride) used as an adjunctive treatment to atypical antipsychotics in the Phase 3 ARISE trial “showed a numerical improvement compared to treatment with a placebo and an atypical antipsychotic.” A company [statement](https://news.bms.com/news/corporate-financial/2025/Bristol-Myers-Squibb-Announces-Topline-Results-from-Phase-3-ARISE-Trial-Evaluating-Cobenfy-xanomeline-and-trospium-chloride-as-an-Adjunctive-Treatment-to-Atypical-Antipsychotics-in-Adults-with-Schizophrenia/default.aspx?ref=fdaweb.com) says the Cobenfy adjunctive treatment was associated with improvement in schizophrenia symptoms.

A subgroup analysis indicated there was a notable difference in response between subjects treated with risperidone as a background therapy compared with the remaining subjects treated with other background antipsychotics, BMS says.

The company says it plans to speak to regulators about next steps once its data analysis is complete.

Cobenfy is indicated to treat schizophrenia in adults.